Module 2: Managing Pain Patients Who Abuse Prescription Drugs (Unaccredited)

Module 2: Completion

Congratulations! You have now completed Module 2: Managing Pain Patients Who Abuse Prescription Drugs (Unaccredited).

To learn more about the safe management of opioid pain medications, please visit Module 1: Safe Prescribing for Pain (Unaccredited).

NIDA offers additional tools and resources for you and your patients, including:

NIDA also provides free drug abuse and addiction curriculum resources for faculty, resident physicians, and medical students through NIDA’s  Centers of Excellence for Physician Information.

References

  1. Smith PC, Schmidt SM, Allensworth-Davies D, Saitz R. A single-question screening test for drug use in primary care. Arch Intern Med. 2010;170:1155-1160.
  2. Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. Pain Medicine. 2005;69:432-442.
  3. Akbik H, Butler SF, Budman SH, Fernandez K, Katz NP, Jamison RN. Validation and clinical application of the Screener and Opioid Assessment for Patients with Pain (SOAPP). J Pain Symptom Manage. 2006;32:287-293.
  4. Substance Abuse and Mental Health Services Administration. Results from the 2011 National Survey on Drug Use and Health: Volume 1. Summary of National Findings. NSDUH Series H-44, HHS Publication No. (SMA) 12-4713. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2012
  5. Centers for Disease Control and Prevention. CDC grand rounds: prescription drug overdoses -- a US epidemic. MMWR Morb Mort Wkly Rep. 2012:61:10-13.
  6. National Institute on Drug Abuse. Research Report Series: Prescription Drugs: Abuse and Addiction. 2011. www.drugabuse.gov/publications/research-reports/misuse-prescription-drugs
  7. Fishbain DA, Rosomoff HL, Rosomoff RS. Drug abuse, dependence, and addiction in chronic pain patients. Clin J Pain. 1992;8:77-85.
  8. Boscarino JA, Rukstalis M, Hoffman SN, et al. Risk factors for drug dependence among out-patinets on opioid therapy in a large US health-care system. Addiction. 2010;105:1776-1782.
  9. Brown J, Setnik B, Lee K, et al. Assessment, stratification, and monitoring of the risk for prescription opioid misuse and abuse in the primary care setting. J Opioid Manag. 2011;7:467-483.
  10. Michna E, Ross EL, Hynes WL, et al. Predicting aberrant drug behavior in patients treated for chronic pain: importance of abuse history. J Pain Symptom Manage. 2004;28:250-258.
  11. Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: a rational approach to the treatment of chronic pain. Pain Med. 2005;6:107-112.
  12. Gourlay DL, Heit HA. Universal precautions revisited: managing the inherited pain patient. Pain Med. 2009;10:S115-S123.
  13. Ballantyne JC, Mao J. Opioid therapy for chronic pain. N Engl J Med. 2003;349:1943-1953.
  14. Eisenberg E, McNicol ED, Carr DB. Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: systematic review and meta-analysis of randomized controlled trials. JAMA. 2005;293:3043-3052.
  15. Martell BA, O’Connor PG, Kerns RD, et al. Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction. Ann Intern Med. 2007;146:116-127.
  16. Passik SD, Kirsh KL. Assessing aberrant drug-taking behaviors in the patient with chronic pain. Curr Pain Headache Res. 2004;8:289-294.
  17. American Medical Association. Informed Consent. American Medical Association 2012. https://www.ama-assn.org/delivering-care/ethics/informed-consent. Accessed 8/9/2012.
  18. Paterick TJ, Carson GV, Allen MC, Paterick TE. Medical informed consent: general considerations for physicians. Mayo Clin Proc. 2008;83:313-319.
  19. Christo PJ, Manchikanti L, Ruan X, et al. Urine drug testing in chronic pain. Pain Physician. 2011;14:123-143.
  20. McCarberg BH. A critical assessment of opioid treatment adherence using urine drug testing in chronic pain management. Postgrad Med. 2011;123:124-131.
  21. Carroll CP, Haythornthwaite J. Maladaptive opioid use behaviors and psychiatric illness: what should we do with what we know? Curr Pain Headache Rep. 2011;15:91-93.
  22. Miller NS, Gold MS. Opiate prescription medication dependence and pain perceptions. J Addict Dis. 2007;26(Suppl 1):65-71.
  23. Weissman DE, Haddox JD. Opioid pseudoaddiction -- an iatrogenic syndrome. Pain. 1989;36:363-366.
  24. Passik SD, Kirsh KL, Whitcomb L, et al. A new tool to assess and document pain outcomes in chronic pain patients receiving opioid therapy. Clin Ther. 2007;26:552-561.
  25. Smith HS, Kirsh KL. Documentation and potential tools in long-term opioid therapy for pain. Anesthesiology Clin. 2007;25:809-823.
  26. Butler SF, Budman SH, Fernandez KC, et al. Development and validation of the Current Opioid Misuse Measure. Pain. 2007;130:144-156.
  27. Weiss RD, Potter JS, Provost SE, et al. A multi-site, two-phase Prescription Opioid Addiction Treatment Study (POATS): rationale, design, and methodology. Contemp Clin Trials. 2010;31:189-199.
  28. Weiss RD, Potter JS, Fiellin DA, et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry. 2011;68:1238-1246.
October 12, 2012